LT2510002T - Antikūnai, neutralizuojantys prolaktino receptorių, ir jų terapinis panaudojimas - Google Patents

Antikūnai, neutralizuojantys prolaktino receptorių, ir jų terapinis panaudojimas

Info

Publication number: LT2510002T
Authority: LT; Lithuania
Prior art keywords: therapeutic use; receptor antibodies; prolactin receptor; neutralizing prolactin; neutralizing
Prior art date: 2009-12-10

Application number

LTEP10776753.5T

Other languages

English (en)

Inventor

Christiane Otto

Siegmund Wolf

Christoph Freiberg

Axel Harrenga

Simone Greven

Mark Trautwein

Sandra Bruder

Andrea Eicker

Andreas Wilmen

Original Assignee

Bayer Intellectual Property Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-12-10

Filing date

2010-11-18

Publication date

2016-11-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42091520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2510002(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-11-18 Application filed by Bayer Intellectual Property Gmbh filed Critical Bayer Intellectual Property Gmbh

2016-11-25 Publication of LT2510002T publication Critical patent/LT2510002T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Neurology (AREA)
Gynecology & Obstetrics (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Microbiology (AREA)
Pregnancy & Childbirth (AREA)
Cell Biology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

LTEP10776753.5T 2009-12-10 2010-11-18 Antikūnai, neutralizuojantys prolaktino receptorių, ir jų terapinis panaudojimas LT2510002T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP09075546A EP2332995A1 (en)	2009-12-10	2009-12-10	Neutralizing prolactin receptor antibodies and their therapeutic use
PCT/EP2010/067747 WO2011069799A1 (en)	2009-12-10	2010-11-18	Neutralizing prolactin receptor antibodies and their therapeutic use

Publications (1)

Publication Number	Publication Date
LT2510002T true LT2510002T (lt)	2016-11-25

Family

ID=42091520

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP10782255.3T LT2510006T (lt)	2009-12-10	2010-11-18	Antikūnai, neutralizuojantys prolaktino receptorių, ir jų terapinis panaudojimas
LTEP10776753.5T LT2510002T (lt)	2009-12-10	2010-11-18	Antikūnai, neutralizuojantys prolaktino receptorių, ir jų terapinis panaudojimas

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP10782255.3T LT2510006T (lt)	2009-12-10	2010-11-18	Antikūnai, neutralizuojantys prolaktino receptorių, ir jų terapinis panaudojimas

Country Status (40)

Country	Link
US (6)	US9649374B2 (lt)
EP (13)	EP2332995A1 (lt)
JP (7)	JP2013513364A (lt)
KR (2)	KR101765968B1 (lt)
CN (6)	CN102858801A (lt)
AP (1)	AP2012006343A0 (lt)
AR (6)	AR079352A1 (lt)
AU (2)	AU2010330165B2 (lt)
BR (2)	BR112012014048B1 (lt)
CA (6)	CA2783514A1 (lt)
CL (2)	CL2012001539A1 (lt)
CR (2)	CR20120310A (lt)
CU (2)	CU20120092A7 (lt)
CY (2)	CY1118209T1 (lt)
DK (2)	DK2510002T3 (lt)
DO (2)	DOP2012000159A (lt)
EA (2)	EA028678B1 (lt)
EC (2)	ECSP12011966A (lt)
ES (2)	ES2610654T3 (lt)
GT (1)	GT201200186A (lt)
HR (2)	HRP20170016T1 (lt)
HU (2)	HUE030143T2 (lt)
IL (2)	IL220151A0 (lt)
IN (2)	IN2012DN05078A (lt)
LT (2)	LT2510006T (lt)
MA (1)	MA33888B1 (lt)
ME (1)	ME02577B (lt)
MX (2)	MX339343B (lt)
NZ (2)	NZ600511A (lt)
PE (3)	PE20171134A1 (lt)
PH (2)	PH12012501129A1 (lt)
PL (2)	PL2510006T3 (lt)
PT (2)	PT2510002T (lt)
RS (2)	RS55589B1 (lt)
SG (2)	SG181513A1 (lt)
SI (2)	SI2510006T1 (lt)
TN (1)	TN2012000294A1 (lt)
TW (5)	TW201138817A (lt)
WO (6)	WO2011069797A1 (lt)
ZA (2)	ZA201204213B (lt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2332995A1 (en) *	2009-12-10	2011-06-15	Bayer Schering Pharma Aktiengesellschaft	Neutralizing prolactin receptor antibodies and their therapeutic use
PH12012501742A1 (en)	2010-03-01	2022-03-21	Bayer Healthcare Llc	Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EP2530089A1 (en)	2011-06-03	2012-12-05	Bayer Pharma Aktiengesellschaft	Neutralising prolactin receptor antibody Mat3 and its therapeutical use
CN104302664B (zh)	2012-03-14	2021-11-26	瑞泽恩制药公司	多特异性抗原结合分子及其用途
US9592297B2 (en) *	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
US8883979B2 (en) *	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
DK2935331T3 (en) *	2012-12-24	2018-06-06	Abbvie Inc	PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF
US20160002342A1 (en) *	2013-03-15	2016-01-07	Xinghang Ma	Anti-prolactin receptor antibody formulations
US9545451B2 (en)	2013-08-21	2017-01-17	Regeneron Pharmaceuticals, Inc.	Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (zh)	2013-08-21	2018-11-21	再生元醫藥公司	抗－ｐｒｌｒ抗體及其用途
EP3139955B1 (en)	2014-04-30	2024-03-20	President and Fellows of Harvard College	Fusion proteins for treating cancer and related methods
KR20170063881A (ko)	2014-10-02	2017-06-08	시티 오브 호프	다가 메디토프, 메디토프 결합 항체 및 이의 용도
EP3252074B1 (en) *	2015-01-30	2025-11-19	Saitama Medical University	Anti-alk2 antibody
NZ737726A (en)	2015-07-06	2023-03-31	Regeneron Pharma	Multispecific antigen-binding molecules and uses thereof
EP3448891A1 (en)	2016-04-28	2019-03-06	Regeneron Pharmaceuticals, Inc.	Methods of making multispecific antigen-binding molecules
IL266917B2 (en)	2016-11-29	2023-10-01	Regeneron Pharma	Anti-human prolactin receptor (prlr) antibody-drug conjugates and use thereof in combination therapy of prlr positive breast cancer
FR3062213B1 (fr) *	2017-01-20	2021-02-26	Endodiag	Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
TW201836647A (zh)	2017-04-06	2018-10-16	美商艾伯維有限公司	抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
WO2018209201A1 (en) *	2017-05-12	2018-11-15	Millennium Pharmaceuticals, Inc.	Treatment of gastroparesis with triazaspiro(4.5)decanone
PE20200481A1 (es)	2017-07-10	2020-03-03	Bayer Pharma AG	Anticuerpo del receptor de prolactina para la perdida de cabello con patrones masculinos y femeninos
SG11202007363TA (en)	2018-02-07	2020-08-28	Regeneron Pharma	Methods and compositions for therapeutic protein delivery
WO2019169330A1 (en) *	2018-03-02	2019-09-06	Oncolix, Inc.	Method for treating cancers expressing prolactin receptor
CN109627340B (zh) *	2018-12-05	2021-02-12	上海交通大学	Cd3和prlr双特异性抗体及其构建与应用
US10467487B1 (en) *	2018-12-11	2019-11-05	Chongqing Jinkang New Energy Automobile Co., Ltd.	Fusion-based traffic light recognition for autonomous driving
CN112425568A (zh) *	2020-12-11	2021-03-02	上海市计划生育科学研究所	一种建立具有emt特征的良性前列腺增生bph犬模型的方法
AR124681A1 (es)	2021-01-20	2023-04-26	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
CN114853890B (zh) *	2022-03-16	2023-04-28	沈阳三生制药有限责任公司	一种prlr抗原结合蛋白及其制备方法和应用
CN114634574B (zh) *	2022-04-18	2022-12-20	先进生物(苏州)有限公司	抗B7H6的scFv抗体、其编码基因及其应用
CN120842398A (zh) *	2023-04-24	2025-10-28	深圳真实生物医药科技有限公司	泌乳素受体抗体及其用途
CN117285625B (zh) *	2023-11-24	2024-01-23	南京佰抗生物科技有限公司	抗泌乳素蛋白的单克隆抗体及应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4657760A (en)	1979-03-20	1987-04-14	Ortho Pharmaceutical Corporation	Methods and compositions using monoclonal antibody to human T cells
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en)	1985-06-26	1993-04-27	Cetus Oncology Corporation	Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
US4986615A (en)	1988-10-17	1991-01-22	The Vendo Company	Vending apparatus
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5225212A (en)	1989-10-20	1993-07-06	Liposome Technology, Inc.	Microreservoir liposome composition and method
GB9105245D0 (en) *	1991-03-12	1991-04-24	Lynxvale Ltd	Binding molecules
CA2103887C (en)	1991-12-13	2005-08-30	Gary M. Studnicka	Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
EP0859841B1 (en)	1995-08-18	2002-06-19	MorphoSys AG	Protein/(poly)peptide libraries
US6110471A (en) *	1996-09-13	2000-08-29	The Board Of Trustees Of The Leland Stanford Junior University	Non-hormonal method of contraception
GB9701425D0 (en)	1997-01-24	1997-03-12	Bioinvent Int Ab	A method for in vitro molecular evolution of protein function
US6867187B2 (en) *	2000-12-22	2005-03-15	Trustees Of The University Of Pennsylvania	Composition and method for modulating somatolactogenic function
EP1325930A1 (en) *	2002-01-08	2003-07-09	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Mammal prolactin variants
US6995244B2 (en) *	2002-12-13	2006-02-07	The Ohio State University	Antagonists for human prolactin
GB0305790D0 (en) *	2003-03-13	2003-04-16	Glaxosmithkline Biolog Sa	Novel Composition
US8192736B2 (en) *	2004-10-28	2012-06-05	Kyowa Hakko Kirin Co., Ltd	Remedy for endometriosis
WO2006089678A2 (en) *	2005-02-22	2006-08-31	Bioinvent International Ab	Antibodies and peptides binding to hiv tat, and uses thereof
GB0517878D0 (en) *	2005-09-02	2005-10-12	Bioinvent Int Ab	Immunotherapeutic treatment
US7422899B2 (en)	2005-10-05	2008-09-09	Biogen Idec Ma Inc.	Antibodies to the human prolactin receptor
CA2932012A1 (en) *	2006-08-18	2008-02-21	Novartis Ag	Prlr-specific antibody and uses thereof
CN102711773A (zh)	2007-05-30	2012-10-03	奥克兰联合服务有限公司	生长激素和相关激素的抑制剂,和其使用方法
EP2025683A1 (en) *	2007-08-13	2009-02-18	INSERM (Institut National de la Santé et de la Recherche Medicale)	Variants of prolactin as antagonists of its receptor
EP2332995A1 (en) *	2009-12-10	2011-06-15	Bayer Schering Pharma Aktiengesellschaft	Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011139375A1 (en) *	2010-05-06	2011-11-10	Ludwig Institute For Cancer Research Ltd	Antibodies directed against carbonic anhydrase ix and methods and uses thereof
GB201020995D0 (en) *	2010-12-10	2011-01-26	Bioinvent Int Ab	Biological materials and uses thereof

2009
- 2009-12-10 EP EP09075546A patent/EP2332995A1/en not_active Withdrawn
2010
- 2010-11-18 WO PCT/EP2010/067744 patent/WO2011069797A1/en not_active Ceased
- 2010-11-18 EP EP12192704A patent/EP2567977A1/en not_active Withdrawn
- 2010-11-18 PT PT107767535T patent/PT2510002T/pt unknown
- 2010-11-18 US US13/514,992 patent/US9649374B2/en active Active
- 2010-11-18 EP EP12192708A patent/EP2567979A1/en not_active Withdrawn
- 2010-11-18 EP EP12192722A patent/EP2567980A1/en not_active Withdrawn
- 2010-11-18 WO PCT/EP2010/067740 patent/WO2011069794A1/en not_active Ceased
- 2010-11-18 EA EA201200860A patent/EA028678B1/ru not_active IP Right Cessation
- 2010-11-18 PH PH1/2012/501129A patent/PH12012501129A1/en unknown
- 2010-11-18 WO PCT/EP2010/067747 patent/WO2011069799A1/en not_active Ceased
- 2010-11-18 EP EP10782255.3A patent/EP2510006B1/en active Active
- 2010-11-18 MX MX2012006620A patent/MX339343B/es active IP Right Grant
- 2010-11-18 CN CN201080063268XA patent/CN102858801A/zh active Pending
- 2010-11-18 HR HRP20170016TT patent/HRP20170016T1/hr unknown
- 2010-11-18 EP EP10781671A patent/EP2510004A1/en not_active Withdrawn
- 2010-11-18 EP EP10784482A patent/EP2510007A1/en not_active Withdrawn
- 2010-11-18 ME MEP-2016-244A patent/ME02577B/me unknown
- 2010-11-18 US US13/514,994 patent/US20120315276A1/en not_active Abandoned
- 2010-11-18 SG SG2012041182A patent/SG181513A1/en unknown
- 2010-11-18 EP EP12192705A patent/EP2567978A1/en not_active Withdrawn
- 2010-11-18 EP EP12192721A patent/EP2570436A1/en not_active Withdrawn
- 2010-11-18 BR BR112012014048-5A patent/BR112012014048B1/pt active IP Right Grant
- 2010-11-18 CN CN201080063269.4A patent/CN102884082B/zh active Active
- 2010-11-18 JP JP2012542435A patent/JP2013513364A/ja not_active Ceased
- 2010-11-18 US US13/514,995 patent/US20130022606A1/en not_active Abandoned
- 2010-11-18 IN IN5078DEN2012 patent/IN2012DN05078A/en unknown
- 2010-11-18 CA CA2783514A patent/CA2783514A1/en not_active Abandoned
- 2010-11-18 AU AU2010330165A patent/AU2010330165B2/en active Active
- 2010-11-18 JP JP2012542431A patent/JP2013513559A/ja active Pending
- 2010-11-18 EP EP12192707A patent/EP2570435A1/en not_active Withdrawn
- 2010-11-18 PE PE2017000782A patent/PE20171134A1/es unknown
- 2010-11-18 EP EP10776753.5A patent/EP2510002B1/en active Active
- 2010-11-18 DK DK10776753.5T patent/DK2510002T3/en active
- 2010-11-18 EA EA201200851A patent/EA029327B1/ru not_active IP Right Cessation
- 2010-11-18 CA CA2783678A patent/CA2783678A1/en not_active Abandoned
- 2010-11-18 LT LTEP10782255.3T patent/LT2510006T/lt unknown
- 2010-11-18 CN CN201080063347.0A patent/CN102947338B/zh active Active
- 2010-11-18 MX MX2012006621A patent/MX2012006621A/es unknown
- 2010-11-18 ES ES10782255.3T patent/ES2610654T3/es active Active
- 2010-11-18 WO PCT/EP2010/067746 patent/WO2011069798A1/en not_active Ceased
- 2010-11-18 DK DK10782255.3T patent/DK2510006T3/en active
- 2010-11-18 JP JP2012542432A patent/JP2013513361A/ja active Pending
- 2010-11-18 AU AU2010330161A patent/AU2010330161B2/en active Active
- 2010-11-18 CA CA2783513A patent/CA2783513C/en active Active
- 2010-11-18 EP EP10779014A patent/EP2510003A1/en not_active Withdrawn
- 2010-11-18 PE PE2012000791A patent/PE20121360A1/es not_active Application Discontinuation
- 2010-11-18 US US13/514,991 patent/US20120321632A1/en not_active Abandoned
- 2010-11-18 WO PCT/EP2010/067743 patent/WO2011069796A1/en not_active Ceased
- 2010-11-18 SG SG2012041166A patent/SG181511A1/en unknown
- 2010-11-18 LT LTEP10776753.5T patent/LT2510002T/lt unknown
- 2010-11-18 EP EP10781882A patent/EP2510005A1/en not_active Withdrawn
- 2010-11-18 RS RS20170010A patent/RS55589B1/sr unknown
- 2010-11-18 PT PT107822553T patent/PT2510006T/pt unknown
- 2010-11-18 CA CA2783651A patent/CA2783651A1/en not_active Abandoned
- 2010-11-18 KR KR1020127017831A patent/KR101765968B1/ko active Active
- 2010-11-18 JP JP2012542434A patent/JP2013513363A/ja active Pending
- 2010-11-18 NZ NZ600511A patent/NZ600511A/en unknown
- 2010-11-18 AP AP2012006343A patent/AP2012006343A0/xx unknown
- 2010-11-18 JP JP2012542436A patent/JP6066474B2/ja active Active
- 2010-11-18 MA MA34951A patent/MA33888B1/fr unknown
- 2010-11-18 BR BR112012015852A patent/BR112012015852B8/pt active IP Right Grant
- 2010-11-18 NZ NZ600512A patent/NZ600512A/en unknown
- 2010-11-18 CA CA2783654A patent/CA2783654A1/en not_active Abandoned
- 2010-11-18 HU HUE10782255A patent/HUE030143T2/en unknown
- 2010-11-18 PL PL10782255T patent/PL2510006T3/pl unknown
- 2010-11-18 US US13/514,993 patent/US20130171147A1/en not_active Abandoned
- 2010-11-18 IN IN5082DEN2012 patent/IN2012DN05082A/en unknown
- 2010-11-18 HR HRP20161401TT patent/HRP20161401T1/hr unknown
- 2010-11-18 PE PE2012000797A patent/PE20121561A1/es not_active Application Discontinuation
- 2010-11-18 PL PL10776753T patent/PL2510002T3/pl unknown
- 2010-11-18 WO PCT/EP2010/067742 patent/WO2011069795A1/en not_active Ceased
- 2010-11-18 HU HUE10776753A patent/HUE031631T2/en unknown
- 2010-11-18 JP JP2012542433A patent/JP2013513362A/ja active Pending
- 2010-11-18 CN CN2010800634488A patent/CN102858803A/zh active Pending
- 2010-11-18 PH PH1/2012/501131A patent/PH12012501131A1/en unknown
- 2010-11-18 RS RS20160915A patent/RS55277B1/sr unknown
- 2010-11-18 CN CN2010800634492A patent/CN102858804A/zh active Pending
- 2010-11-18 KR KR1020127017833A patent/KR101790366B1/ko active Active
- 2010-11-18 SI SI201031367A patent/SI2510006T1/sl unknown
- 2010-11-18 CA CA2783610A patent/CA2783610C/en active Active
- 2010-11-18 ES ES10776753.5T patent/ES2603352T3/es active Active
- 2010-11-18 SI SI201031312A patent/SI2510002T1/sl unknown
- 2010-11-18 US US13/514,996 patent/US9241989B2/en active Active
- 2010-11-18 CN CN2010800633485A patent/CN102741291A/zh active Pending
- 2010-12-10 TW TW099143326A patent/TW201138817A/zh unknown
- 2010-12-10 AR ARP100104567A patent/AR079352A1/es active IP Right Grant
- 2010-12-10 AR ARP100104566A patent/AR079351A1/es unknown
- 2010-12-10 TW TW099143330A patent/TW201130506A/zh unknown
- 2010-12-10 AR ARP100104565A patent/AR079350A1/es unknown
- 2010-12-10 TW TW099143327A patent/TW201130504A/zh unknown
- 2010-12-10 AR ARP100104563A patent/AR079348A1/es active IP Right Grant
- 2010-12-10 TW TW099143332A patent/TWI508744B/zh active
- 2010-12-10 AR ARP100104564A patent/AR079349A1/es unknown
- 2010-12-10 TW TW099143328A patent/TWI487536B/zh active
- 2010-12-17 AR ARP100104707A patent/AR079641A1/es unknown
2012
- 2012-06-04 IL IL220151A patent/IL220151A0/en active IP Right Grant
- 2012-06-04 IL IL220149A patent/IL220149A/en active IP Right Grant
- 2012-06-07 CU CU2012000092A patent/CU20120092A7/es unknown
- 2012-06-07 CU CU2012000093A patent/CU23973B1/es not_active IP Right Cessation
- 2012-06-08 GT GT201200186A patent/GT201200186A/es unknown
- 2012-06-08 CL CL2012001539A patent/CL2012001539A1/es unknown
- 2012-06-08 EC ECSP12011966 patent/ECSP12011966A/es unknown
- 2012-06-08 ZA ZA2012/04213A patent/ZA201204213B/en unknown
- 2012-06-08 TN TNP2012000294A patent/TN2012000294A1/en unknown
- 2012-06-08 DO DO2012000159A patent/DOP2012000159A/es unknown
- 2012-06-08 CR CR20120310A patent/CR20120310A/es unknown
- 2012-06-08 CL CL2012001540A patent/CL2012001540A1/es unknown
- 2012-06-08 CR CR20120312A patent/CR20120312A/es unknown
- 2012-06-08 EC ECSP12011965 patent/ECSP12011965A/es unknown
- 2012-06-08 DO DO2012000160A patent/DOP2012000160A/es unknown
- 2012-06-08 ZA ZA2012/04214A patent/ZA201204214B/en unknown
2015
- 2015-07-03 JP JP2015134286A patent/JP6199930B2/ja active Active
2016
- 2016-10-31 CY CY20161101101T patent/CY1118209T1/el unknown
2017
- 2017-01-10 CY CY20171100030T patent/CY1118407T1/el unknown

Also Published As

Publication number	Publication date
CN102884082A (zh)	2013-01-16
CA2783513A1 (en)	2011-06-16
CL2012001539A1 (es)	2012-10-12
JP2013513361A (ja)	2013-04-22
MX2012006620A (es)	2012-06-21
US20130129739A1 (en)	2013-05-23
US9241989B2 (en)	2016-01-26
TWI487536B (zh)	2015-06-11
RS55589B1 (sr)	2017-06-30
EA028678B1 (ru)	2017-12-29
US20130272968A1 (en)	2013-10-17
EP2567980A1 (en)	2013-03-13
TW201130507A (en)	2011-09-16
CN102858804A (zh)	2013-01-02
PT2510002T (pt)	2016-11-23
CA2783610C (en)	2018-10-30
HRP20170016T1 (hr)	2017-02-24
US20120315276A1 (en)	2012-12-13
TW201130505A (en)	2011-09-16
TN2012000294A1 (en)	2013-12-12
CU23973B1 (es)	2013-12-27
US20130171147A1 (en)	2013-07-04
CY1118209T1 (el)	2017-06-28
US20130022606A1 (en)	2013-01-24
CN102858803A (zh)	2013-01-02
EP2567979A1 (en)	2013-03-13
CN102884082B (zh)	2015-05-20
EP2510005A1 (en)	2012-10-17
JP2013513559A (ja)	2013-04-22
CA2783651A1 (en)	2011-06-16
KR20120112528A (ko)	2012-10-11
GT201200186A (es)	2014-01-06
PT2510006T (pt)	2017-01-20
BR112012015852A2 (pt)	2017-05-23
EP2510006B1 (en)	2016-11-09
AU2010330161B2 (en)	2015-07-09
BR112012014048A2 (pt)	2017-10-31
AU2010330165A1 (en)	2012-07-19
JP2013513363A (ja)	2013-04-22
HK1180354A1 (en)	2013-10-18
AR079350A1 (es)	2012-01-18
EP2510007A1 (en)	2012-10-17
ZA201204214B (en)	2014-08-27
ES2603352T3 (es)	2017-02-27
HK1180700A1 (en)	2013-10-25
IN2012DN05078A (lt)	2015-10-23
CU20120093A7 (es)	2012-10-15
RS55277B1 (sr)	2017-02-28
HRP20161401T1 (hr)	2016-12-16
CA2783513C (en)	2018-08-14
PE20121561A1 (es)	2012-11-25
CA2783514A1 (en)	2011-06-16
AR079348A1 (es)	2012-01-18
EP2567978A1 (en)	2013-03-13
IN2012DN05082A (lt)	2015-10-09
DK2510006T3 (en)	2017-01-23
DOP2012000160A (es)	2012-09-30
ZA201204213B (en)	2014-08-27
WO2011069798A1 (en)	2011-06-16
DK2510002T3 (en)	2016-11-28
US9649374B2 (en)	2017-05-16
KR20120112527A (ko)	2012-10-11
CN102947338A (zh)	2013-02-27
WO2011069799A1 (en)	2011-06-16
WO2011069795A4 (en)	2011-08-18
ME02577B (me)	2017-06-20
WO2011069797A1 (en)	2011-06-16
NZ600512A (en)	2014-11-28
TW201130506A (en)	2011-09-16
PL2510002T3 (pl)	2017-02-28
ECSP12011966A (es)	2012-07-31
EP2510003A1 (en)	2012-10-17
WO2011069794A1 (en)	2011-06-16
JP2013513362A (ja)	2013-04-22
HUE030143T2 (en)	2017-04-28
TWI508744B (zh)	2015-11-21
AR079641A1 (es)	2012-02-08
BR112012015852B1 (pt)	2020-12-29
BR112012014048B1 (pt)	2021-10-26
CA2783610A1 (en)	2011-06-16
KR101790366B1 (ko)	2017-10-26
CR20120310A (es)	2012-08-01
MX2012006621A (es)	2012-10-05
IL220149A0 (en)	2012-07-31
HUE031631T2 (en)	2017-07-28
SG181513A1 (en)	2012-07-30
SI2510006T1 (sl)	2017-02-28
TW201138817A (en)	2011-11-16
CA2783654A1 (en)	2011-06-16
SI2510002T1 (sl)	2016-12-30
ES2610654T3 (es)	2017-04-28
AP2012006343A0 (en)	2012-06-30
CN102858801A (zh)	2013-01-02
EA029327B1 (ru)	2018-03-30
EP2510006A1 (en)	2012-10-17
EP2567977A1 (en)	2013-03-13
JP2015180690A (ja)	2015-10-15
AR079349A1 (es)	2012-01-18
CN102947338B (zh)	2015-11-25
DOP2012000159A (es)	2012-09-30
CR20120312A (es)	2012-08-27
EA201200860A1 (ru)	2013-01-30
JP6066474B2 (ja)	2017-01-25
EP2332995A1 (en)	2011-06-15
PE20171134A1 (es)	2017-08-09
EP2570436A1 (en)	2013-03-20
JP2013513365A (ja)	2013-04-22
PH12012501129A1 (en)	2012-11-05
EP2510002B1 (en)	2016-08-24
PL2510006T3 (pl)	2017-06-30
BR112012015852A8 (pt)	2017-06-27
IL220149A (en)	2017-09-28
CA2783678A1 (en)	2011-06-16
WO2011069796A1 (en)	2011-06-16
BR112012015852B8 (pt)	2021-05-25
IL220151A0 (en)	2012-07-31
NZ600511A (en)	2014-01-31
CN102741291A (zh)	2012-10-17
MX339343B (es)	2016-05-20
US20120321632A1 (en)	2012-12-20
CY1118407T1 (el)	2017-06-28
AU2010330161A1 (en)	2012-07-05
JP2013513364A (ja)	2013-04-22
TW201130504A (en)	2011-09-16
CU20120092A7 (es)	2012-10-15
EP2510004A1 (en)	2012-10-17
EP2510002A1 (en)	2012-10-17
KR101765968B1 (ko)	2017-08-08
AR079352A1 (es)	2012-01-18
LT2510006T (lt)	2016-12-12
EA201200851A1 (ru)	2013-01-30
CL2012001540A1 (es)	2013-01-18
PH12012501131A1 (en)	2017-08-23
PE20121360A1 (es)	2012-10-11
SG181511A1 (en)	2012-07-30
MA33888B1 (fr)	2013-01-02
EP2570435A1 (en)	2013-03-20
AR079351A1 (es)	2012-01-18
AU2010330165B2 (en)	2015-07-16
ECSP12011965A (es)	2012-07-31
WO2011069795A1 (en)	2011-06-16
JP6199930B2 (ja)	2017-09-20

Publication	Publication Date	Title
ZA201204214B (en)	2014-08-27	Neutralizing prolactin receptor antibodies and their therapeutic use
IL221620A (en)	2017-04-30	Antagonist antibodies against the interleukin receptor 7 and methods for their use
ZA201600335B (en)	2017-11-29	Human cytomegalovirus neutralizing antibodies and use thereof
IL221288A0 (en)	2012-10-31	Therapeutic methods using anti-cd200 antibodies
ZA201202116B (en)	2018-11-28	Neutralizing antibodies to hiv-1 and their use
IL226399A0 (en)	2013-07-31	Human antibodies to the glucagon receptor
HUE058226T2 (hu)	2022-07-28	NGF elleni antitestek és alkalmazásuk
IL229504A0 (en)	2014-01-30	Mat3 antibody neutralizing prolactin receptor and its medical use
EP2475683A4 (en)	2013-04-24	GLUCAGONIC RECEPTOR ANTIBODY YOUR USE
ZA201201287B (en)	2013-05-29	Therapeutic aryl-amido-aryl compounds and their use
IL226635B (en)	2019-09-26	Human anti-sod1 antibodies
GB0913955D0 (en)	2009-09-16	Lactams and their therapeutic use